No profile data available.
4D Molecular Therapeutics, Inc. (FDMT) is a healthcare company in the lung treatment pharmaceuticals industry, based in EmeryVille, United States, with about 196 full-time employees.
It reported revenue of $85.21 million for fiscal year 2025, up 230194.6% from fiscal year 2024, and net income of -$140.11 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $3.78 million, up 25106.7% from a year before. Japan was its largest region in fiscal year 2025, with 100% of revenue. Its market capitalization was $736.41 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
4D Molecular Therapeutics reported $85.21 million in revenue for fiscal year 2025, up 230194.6% from $37,000 in fiscal year 2024. In Q2 2026 revenue was $3.78 million.
Japan: 100% of revenue by region in fiscal year 2025, followed by United States (under 1%).
$736.41 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Upstream Bio, Inc. (UPB), Savara Inc. (SVRA), Gyre Therapeutics, Inc. (GYRE), Sionna Therapeutics, Inc. (SION).